Emmanuel Sunday Omirin

Emmanuel Sunday Omirin

Auto-generated profile, based on publicly available information

Emmanuel Sunday Omirin

Cell and Molecular Biology Unit, Eureka Research Laboratory, Babcock University, Ilishan-Remo, Nigeria

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2024 in In Silico Pharmacology
Verified
Journal Article
Closed access
PDF file
EOEmmanuel Sunday Omirin
Emmanuel Sunday Omirin
PAPrecious Oluwasanmi Aribisala
Precious Oluwasanmi Aribisala
EOEzekiel Abiola Olugbogi
Ezekiel Abiola Olugbogi
OAOlawole Yakubu Adeniran
Olawole Yakubu Adeniran
SESunday Adeola Emaleku
Sunday Adeola Emaleku
IWIheanyichukwu Wopara
Iheanyichukwu Wopara

23 December 2024
Verified
Journal Article
Open access
PDF file
OOOlukayode Olusola Odubela
Olukayode Olusola Odubela
EOEmmanuel Sunday Omirin
Emmanuel Sunday Omirin
AOAfeez John Olanrewaju
Afeez John Olanrewaju
EOEzekiel Abiola Olugbogi
Ezekiel Abiola Olugbogi
PAPrecious Oluwasanmi Aribisala
Precious Oluwasanmi Aribisala
SBSamuel Oluwaseun Boboye
Samuel Oluwaseun Boboye
The target of most cancer chemotherapeutic agents is to drive cancer cells toward death, necessitating the need to find a fine balance between anti-apoptotic and pro-apoptotic proteins in maintaining cellular homeostasis. Any shift favoring the pro-apoptotic proteins is needed to drive cellular death in cancer chemotherapy. Therefore, this study uses molecular docking, ADMET predictions, and molecular dynamics simulations for the identification of potent inhibitors of anti-apoptotic Bcl-2 from Morus alba (mulberry). Our molecular docking study discovered that quercetin-3-(6- malonylglucoside) (-10.912kcal/mol) and epigallocatechin gallate (-9.750kcal/mol) recorded excellent binding affinity against human Bcl-2, better than popular standard drugs, venetoclax (-9.468(kcal/mol) and navitoclax (-9.058kcal/mol). Interactions profile summary clearly showed that hydrophobic interactions at TRP141, VAL145, and TYR105 were consistently maintained by the ligands, and all the compounds, except venetoclax, consistently maintained the hydrogen bonding at TYR105. MD simulation analysis showed that the protein and ligand RMSD for the quercetin-3-(6-malonylglucoside)-Bcl-2 complex fell within permissible range, suggesting the ligand is capable of functioning as apposite antagonists of Bcl-2. Epigallocatechin gallate also bind excellently with the target, and both ligands showed favorable ADMET parameters. Summarily, this study identifies two compounds of mulberry as potential drug candidate in the management of known human malignancies, and therefore suggest the compounds should further be assessed through in vitro and in vivo approaches to validate the reports documented here.

4 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EOEmmanuel Sunday Omirin
Emmanuel Sunday Omirin
OOOlaposi Idowu Omotuyi
Olaposi Idowu Omotuyi
OAOluwaseun Grace Afokhume
Oluwaseun Grace Afokhume
EOEhisdiame Favour Okoh
Ehisdiame Favour Okoh
SBSamuel Oluwaseun Boboye
Samuel Oluwaseun Boboye
OAOluwafemi Ojo Agosile
Oluwafemi Ojo Agosile
The target of most cancer chemotherapeutic agents is to drive cancer cells toward death. A fine balance between anti-apoptotic and pro-apoptotic proteins is needed to maintain cellular homeostasis. Any shift favoring the pro-apoptotic ones is needed to drive cellular death in cancer chemotherapy. However, anti-apoptotic proteins such as Bcl-2 and Bcl-xL bind with pro-apoptotic proteins to hinder apoptosis mechanisms. Overexpression of these anti-apoptotic proteins lead to several cancers by preventing apoptosis. In this study, molecular docking, ADMET predictions, and molecular dynamics simulations were performed for the identification of potent inhibitors of anti-apoptotic Bcl-2 with compounds of Morus alba. Our study discovered that Quercetin-3-(6-Malonylglucoside) and Epigallocatechin gallate recorded excellent binding affinity with Bcl-2. Therefore, we conclude that compounds of Morus alba should be subjected to further experimental studies ( in vitro and in vivo) in order to confirm the findings that they could be used as better options in cancer chemotherapy.

22 June 2023 in Research Square
Verified
Preprint
Open access
PDF file
OAOluwafemi Ojo Agosile
Oluwafemi Ojo Agosile
PNPrisca Chinonso Njoku
Prisca Chinonso Njoku
UOUgochukwu Oduwe
Ugochukwu Oduwe
AAAyokanmi Joseph Aremu
Ayokanmi Joseph Aremu
SFSunday Joseph Fajobi
Sunday Joseph Fajobi
EOEmmanuel Sunday Omirin
Emmanuel Sunday Omirin
More than 19 percent of all human cancer cases globally express mutant RAS proteins, which are the most frequently altered oncogenic proteins. Targeting cancer cells becomes difficult because these oncogenic proteins and cancer cells that are driven by Ras mutation show very aggressive traits. KRAS is the most expressed among the three isoforms of Ras mutation, which usually occur at position 12. KRAS G12C and KRAS G12D are common types of KRAS that have been proven difficult to target for many years. In recent times, many studies started to show that a lot of food spices possess strong anticancer properties that can target many cancer cells. Therefore, computational methods to access the anticancer properties of some selected compounds that are present in common food spices against KRAS G12C and KRAS G12D in their inactive GDP-bound state. These compounds were molecularly docked with standard drugs after their ADMET screening revealed their druglikeness. Chlorogenic acid and Rosmarinic acid displayed better binding affinity to the targets than all other drugs studied in this research. Molecular dynamics simulation was used to verify this compound's stability. Therefore, after extensive experimental effort, it is most likely that Rosmarinic acid would be effective as a KRAS G12C medicine.

28 August 2026 in Bulletin of the National Research Centre
Verified
Journal Article
Open access
PDF file
OSOladimeji Soremekun
Oladimeji Soremekun
PAPaul Ademola Adeleke
Paul Ademola Adeleke
LALeviticus Arietarhire
Leviticus Arietarhire
EOEzekiel Abiola Olugbogi
Ezekiel Abiola Olugbogi
SOSunday Omirin
Sunday Omirin
SUSolomon Umukoro
Solomon Umukoro
Introduction: The misuse and abuse of tramadol, a synthetic opioid analgesic, has become a major public health concern in Africa. Although effective for managing moderate to severe pain, tramadol exposure has been associated with central nervous system toxicity. Hibiscus sabdariffa , commonly consumed as “Zobo,” contains bioactive substances with potent antioxidant and anti-inflammatory properties. Therefore, this study investigated the neuroprotective potential of aqueous H. sabdariffa extract (HSE) against tramadol-induced neurotoxicity in male Swiss mice. Methodology: Fifty adult male mice were randomly assigned into five groups namely control (normal saline), tramadol (50 mg/kg), and three treatment groups receiving tramadol intraperitoneally plus HSE given through oral route at 50, 100, and 200 mg/kg for 21 days. Neurobehavioral tests assessed motor coordination, cognition, anxiety, and depressive-like behaviors. Brain regions, including the hippocampus, prefrontal cortex, and cerebellum, were analyzed for malondialdehyde, reduced glutathione, catalase, superoxide dismutase, glutathione-S-transferase, nitrite levels, acetylcholinesterase activity, and pro-inflammatory cytokines, including interleukin-6, and tumour necrosis factor-alpha. Histological analysis was performed using Nissl staining, while RT-PCR quantified neurotransmission- and apoptosis-related genes, including GAD2, TH, TP53, BAX, and BCL-2. Molecular docking evaluated interactions of H. sabdariffa phytocompounds with target proteins. Results: Tramadol exposure significantly impaired behavior, increased oxidative stress and inflammation, depleted antioxidant defenses, and induced neuronal damage with altered gene expression. H. sabdariffa extract treatment dose-dependently mitigated these alterations, preserved neuronal architecture, and modulated apoptosis-related genes. Docking computation identified Quercetin-3-O-rutinoside, Baicalin, and Delphinidin-3-O-sambubioside as hit compounds with strong binding affinity to target proteins of the genes evaluated in the RT-PCR. Conclusion: Hibiscus sabdariffa aqueous extract activity suggests robust neuroprotective effects against tramadol-induced neurotoxicity through coordinated antioxidant, anti-inflammatory, anti-apoptotic, and neuromodulatory mechanisms. These findings position H. sabdariffa extract as a promising, accessible therapeutic candidate for managing opioid-induced CNS damage.